Physician profile
Virginia Smith
NPI 1558616557
$4,843.20
in general payments reported to CMS, 2019-2025
22 companies · $1,444 in 2025
The $1,444 reported for 2025 was more than what 92% of Primary Care providers received nationally (typical 2025 total: $170).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,100 · 2022: $1,151 · 2023: $494 · 2024: $654 · 2025: $1,444.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,592.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,592.39 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,227.82 | 2021-2025 | |
| Novo Nordisk INC | $719.62 | 2021-2025 | Wegovy, Ozempic |
| Astrazeneca Pharmaceuticals LP | $577.26 | 2021-2025 | Airsupra, Breztri, Fasenra |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $400.18 | 2022-2025 | Caplyta |
| Axsome Therapeutics, INC. | $397.60 | 2024-2025 | Auvelity, Symbravo |
| Bayer Healthcare Pharmaceuticals INC. | $196.66 | 2021-2023 | |
| Biohaven Pharmaceuticals, INC. | $196.47 | 2021 | |
| Janssen Pharmaceuticals, INC | $143.78 | 2021-2022 | |
| Phathom Pharmaceuticals, INC. | $125.00 | 2024 | Voquezna |
| Tris Pharma INC | $123.57 | 2024 | Quillichew Er, Dyanavel Xr, Quillivant |
| Idorsia Pharmaceuticals US INC | $111.39 | 2023 | Quviviq |
| Urovant Sciences INC | $104.10 | 2022 | |
| Ardelyx, INC. | $103.11 | 2023 | Ibsrela |
| Pharmacosmos Therapeutics INC. | $92.77 | 2021-2022 | |
| Genentech USA, INC. | $81.85 | 2021 |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Teva Pharmaceuticals USA, INC. | $64.97 | 2024 | Austedo Xr |
| Otsuka America Pharmaceutical, INC. | $57.18 | 2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $41.49 | 2021-2022 | |
| Sunovion Pharmaceuticals INC. | $23.30 | 2022 | |
| Pfizer INC. | $20.52 | 2022 | |
| Optinose US, INC. | $19.45 | 2022 | |
| Merck Sharp & Dohme LLC | $15.11 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Virginia Smith listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.